AIDS-associated Toxoplasmosis

Global HIV/AIDS Medicine

Volumn , Issue , 2008, Pages 399-413

  Subauste, Carlos S ^a   Montoya, Jose G ^b   Remington, Jack S ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053653143     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2882-6.50040-X     Document Type: Chapter

References (158)

1. Luft BJ, Brooks RG, Conley FK, et al. TE in patients with acquired immune deficiency syndrome. JAMA 1984, 252:913-917.
2. Luft BJ, Castro KG An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: Implication for future therapeutic trials. Eur J Clin Microbiol Infect Dis 1991, 10:178-181.
3. Remington JS, McLeod R, Desmonts G Toxoplasmosis. Infectious diseases of the fetus and newborn infant 1995, 140-267. W.B. Saunders, Philadelphia. 4th edn. J.S. Remington, J.O. Klein (Eds.).
4. Grant IH, Gold JWM, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis. AIDS 1990, 4:519-521.
5. Israelski DM, Chmiel JS, Poggensee L, et al. Prevalence of toxoplasma infection in a cohort of homosexual men at risk of AIDS and TE. J AIDS 1993, 6:414-418.
6. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 1999, 48:1-22.
7. Antinori A, Larussa D, Cingolani A, et al. Prevalence, associated factors, and prognostic determinants of AIDS-related TE in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004, 39:1681-1691.
8. Luft BJ, Conley F, Remington JS, et al. Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet 1983, 1:781-784.
9. Navia BA, Petito CK, Gold JW, et al. Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients. Ann Neurol 1986, 19:224-238.
10. Selik RM, Starcher ET, Curran JW Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987, 1:175-182.
11. Wong B, Gold JWM, Brown AE, et al. Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers. Ann Intern Med 1984, 100:36-42.
12. Montoya JG, Kovacs JA, Remington J Toxoplasmosis. Principles and practice of infectious diseases 2005, 2:3170-3198. Churchill Livingstone, Edinburgh. 6th edn. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
13. Leport C, Raffi F, Matheron S, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine-sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med 1988, 84:94-100.
14. Dannemann BR, McCutchan JA, Israelski DA, et al. Treatment of TE in patients with AIDS: A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992, 116:33-43.
15. Haverkos HW, Remington JS, Chan JC Assessment of Toxoplasma encephalitis (TE) therapy; A cooperative study. Am J Med 1987, 82:907-914.
16. Levy RM, Bredesen DE Central nervous system dysfunction in acquired immunodeficiency syndrome. J AIDS 1988, 1:41-64.
17. Porter SB, Sande M Toxoplasmosis of the central nervous system in the Acquired Immunodeficiency Syndrome. N Engl J Med 1992, 327:1643-1648.
18. Renold C, Sugar A, Chave J-P, et al. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine 1992, 71:224-239.
19. Pedrol E, Gonzales-Clemente JM, Gatell JM, et al. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS 1990, 4:511-517.
20. Carrazana E, Rossitch E, Martinez J Unilateral 'akathisia' in a patient with AIDS and a toxoplasmosis subthalamic abscess. Neurology 1989, 39:449-450.
21. Carrazana EJ, Rossitch EJ, Samuels MA Parkinsonian symptoms in a patient with AIDS and cerebral toxoplasmosis. J Neurol Neurosurg Psychiatry 1989, 52:1445-1446.
22. Koppel BS Daras M. 'Rubrual' tremor due to midbrain Toxoplasmosis abscess. Mov Disord 1990, 5:254-256.
23. Tolge CF, Factor SA Focal dystonia secondary to cerebral toxoplasmosis in a patient with acquired immune deficiency syndrome. Mov Disord 1991, 6:69-72.
24. Herskovitz S, Siegel SE, Schneider AT, et al. Spinal cord toxoplasmosis in AIDS. Neurol 1989, 39:1552-1553.
25. Mehren M, Burns PJ, Mamani F, et al. Toxoplasmic myelitis mimicking intramedullary spinal cord tumor. Neurology 1988, 38:1648-1650.
26. Gray F, Gherardi R, Wingate E, et al. Diffuse 'encephalitic' cerebral toxoplasmosis in AIDS: Report of four cases. J Neurol 1989, 236:273-277.
27. Lucet J-C, Bailly M-P, Bedos J-P, et al. Septic shock due to Toxoplasmosis in patients infected with the human immunodeficiency virus. Chest 1993, 104:1054-1058.
28. Oksenhendler E, Cadranel J, Sarfati C, et al. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am J Med 1990, 88:18N-21N.
29. Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. Medicine 1994, 73:306-314.
30. Tschirhart D, Klatt E Disseminated toxoplasmosis in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1988, 112:1237-1241.
31. Derouin F, Sarfati C, Beauvais B, et al. Prevalence of pulmonary toxoplasmosis in HIV-infected patients. AIDS 1990, 4:1036.
32. Schnapp L, Geaghan S, Campagna A, et al. Toxoplasma gondii pneumonitis in Patients Infected with the Human Immunodeficiency Virus. Arch Intern Med 1992, 1521073-1521076.
33. Charles PE, Doise JM, Quenot JP, et al. An unusual cause of acute respiratory distress in a patient with AIDS: primary infection with Toxoplasma gondii. Scand J Infect Dis 2003, 35:901-902.
34. Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al. Ocular Toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophth 1992, 114:130-135.
35. Friedman DI Neuro-ophthalmic manifestations of human immunodeficiency virus infection. Neurol Clin 1991, 9:55-72.
36. Gagliuso D, Teich S, Friedman A, et al. Ocular toxoplasmosis in AIDS patients. Trans Am Ophth Soc 1990, 88:63-88.
37. Holland G, Engstrom R, Glasgow B, et al. Ocular toxoplasmosis in patients with acquired immunodeficiency syndrome. Am J Opthalmol 1988, 106:653-667.
38. Eliaszewicz M, Lecomte I, De Sa M. Relation between decreasing serial CD4 lymphocyte count and outcome of toxoplasmosis in AIDS patients: a basis for primary prophylaxis. 6th International Conference on AIDS, San Francisco, CA: 1990.
39. Araujo FG, Guptill DR, Remington JS In vivo activity of piritrexim against Toxoplasma gondii. J Infect Dis 1987, 156:828-830.
40. Matheron S, Dournon E, Garakhanian S, et al. Prevalence of toxoplasmosis in 365 AIDS and ARC patients before and during zidovudine treatment. 6th International Conference on AIDS, San Francisco, CA: 1990.
41. Miro JM, Buira E, Mallolas J, et al. Relation between CD4+ lymphocyte counts, tuberculosis, other opportunistic infections(OI) or Kaposis's sarcoma (KS) in Spanish AIDS Patients. VIIth International Conference on AIDS, Florence, Italy 1991.
42. Oksenhendler E, Charreau I, Tournerie C, et al. Toxoplasma gondii in advanced HIV infection. AIDS 1994, 8:483-487.
43. Minkoff H, Remington JS, Holman S, et al. Vertical transmission of toxoplasma by human immunodeficiency virus-infected women. Am J Obstet Gynecol 1997, 176:555-559.
44. Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 1996, 68:93-96. Anon.
45. Mitchell CD, Lewis L, McLellan S, et al. Increased risk of congential toxoplasmosis (Ct) among infants born to mothers infected with HIV-1 and Toxoplasma gondii. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC: 28 January-1 February 1996.
46. Mitchell CD, Erlich SS, Mastrucci MT, et al. Congenital toxoplasmosis occurring in infants perinatally infected with human immunodeficiency virus 1. Pediatr Infect Dis J 1990, 9:512-518.
47. Cimino C, Lipton RB, Williams A, et al. The evaluation of patients with human immunodeficiency virus-related disorders and brain mass lesions. Arch Intern Med 1991, 151:1381-1384.
48. Tachikawa N, Goto M, Hoshino Y, et al. Detection of Toxoplasma gondii, Epstein-Barr virus, and JC virus DNAs in the cerebrospinal fluid in acquired immunodeficiency syndrome patients with focal central nervous system complications. Intern Med 1999, 38:556-562.
49. Suzuki Y, Israelski DM, Dannemann BR, et al. Diagnosis of TE in patients with acquired immunodeficiency syndrome by using a new serologic method. J Clin Microbiol 1988, 26:2541-2543.
50. Orefice G, Carrieri PB, de Marinis T, et al. Use of the intrathecal synthesis of antitoxoplasma antibodies in the diagnostic assessment and in the follow-up of AIDS patients with cerebral toxoplasmosis. Acta Neurol (Napoli) 1990, 12:79-81.
51. Potasman I, Resnick L, Luft BJ, et al. Intrathecal production of antibodies against Toxoplasma gondii in patients with TE and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988, 108:49-51.
52. Verbraak FD, Galema M, van den Hans Horn G, et al. Serological and polymerase chain re action-based analysis of aqueous humour samples in patients with AIDS and necrotizing retinitis. AIDS 1996, 10:1091-1099.
53. Chakroun M, Meyohas MC, Pelosse B, et al. Émergence de la toxoplasmose oculaire au cours du SIDA. [Emergence of ocular toxoplasmosis in AIDS]. Ann Med Interne (Paris) 1990, 141:472-474.
54. Borges AS, Figueiredo JF [Detection of anti-Toxoplasma gondii IgG, IgM and IgA immunoglobulins in the serum, cerebrospinal fluid and saliva of patients with acquired immunodeficiency syndrome and neurotoxoplasmosis]. Arq Neuropsiquiatr 2004, 62:1033-1037.
55. Stepick-Biek P, Thulliez P, Araujo FG, et al. IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis 1990, 162:270-273.
56. Pinon JM, Toubas D, Marx C, et al. Detection of specific immunoglobulin E in Patients with toxoplasmosis. J Clin Microbiol 1990, 28:1739-1743.
57. Wong SY, Hadju M-P, Ramirez R, et al. The role of specific immunoglobulin E in diagnosis of acute toxoplasma infection and toxoplasmosis. J Clin Microbiol 1993, 31:2952-2959.
58. Derouin F, Mazeron MC, Garin YJ Comparative study of tissue culture and mouse inoculation methods for demonstration of Toxoplasma gondii. J Clin Microbiol 1987, 25:1597-1600.
59. Hofflin JM, Remington JS Tissue culture isolation of Toxoplasma from blood of a patient with AIDS. Arch Intern Med 1985, 145:925-926.
60. Tirard V, Niel G, Rosenheim M, et al. Diagnosis of toxoplasmosis in patients with AIDS by isolation of the parasite from the blood. N Engl J Med 1991, 324:632.
61. Derouin F, Sarfati C, Beauvais B, et al. Laboratory diagnosis of pulmonary toxoplasmosis in patients with acquired immunodeficiency syndrome. J Clin Microbiol 1989, 27:1661-1663.
62. van de Ven E, Melchers W, Galama J, et al. Identification of Toxoplasma gondii infections by BI gene amplification. J Clin Microbiol 1991, 19:2120-2124.
63. Burg J, Grover C, Pouletty P, et al. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol 1989, 27:1787-1792.
64. Dupon M, Cazenave J, Pellegrin J-L, et al. Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients. J Clin Microbiol 1995, 33:2421-2426.
65. Ostergaard L, Nielsen AK, Black FT DNA amplification on cerebrospinal fluid for diagnosis of cerebral toxoplasmosis among HIV-positive patients with signs or symptoms of neurological disease. Scand J Infect Dis 1993, 25:227-237.
66. Parmley SF, Goebel FD, Remington JS Detection of Toxoplasma gondii DNA in cerebrospinal fluid from AIDS patients by polymerase chain reaction. J Clin Microbiol 1992, 30:3000-3002.
67. Bretagne S, Costa J-M, Fleury-Feith J, et al. Quantitative competitive PCR with bronchoalveolar lavage fluid for diagnosis of toxoplasmosis in AIDS patients. J Clin Microbiol 1995, 33:1662-1664.
68. Dupouy-Camet J, de Lavareda Souza L, Maslo C, et al. Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction. J Clin Microb 1993, 31:1866-1869.
69. Filice G, Hitt J, Mitchell C, et al. Diagnosis of toxoplasma parasitemia in patients with AIDS by gene detection after amplification with polymerase chain reaction. J Clin Microb 1993, 31:2327-2331.
70. Pelloux H, Dupouy-Camet J, Derouin F, et al. A multicentre prospective study for the polymerase chain reaction detection of Toxoplasma gondii DNA in blood samples from 186 AIDS patients with suspected TE. Bio-Toxo Study Group. AIDS 1997, 11:1888-1890.
71. Montoya JG, Parmley S, Liesenfeld O, et al. Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmology 1999, 106:1554-1563.
72. Post MJ, Kursunoglu SJ, Hensley GT, et al. Cranial CT in acquired immunodeficiency syndrome: spectrum of diseases and optimal contrast enhancement technique. AJR Am J Roentgenol 1985, 145:929-940.
73. Strittmatter C, Lang W, Wiestler OD, et al. The changing pattern of human immunodeficiency virus associated cerebral toxoplasmosis: a study of 46 postmortem cases. Acta Neuropathol 1992, 83:475-481.
74. Levy RM, Breit R, Russell E, et al. MRI-guided stereotaxic brain biopsy in neurologically symptomatic AIDS patients. J Acquir Immune Defic Syndr 1991, 4:254-260.
75. Post MJ, Chan JC, Hensley GT, et al. Toxoplasma encephalitis in Haitian adults with acquired immunodeficiency syndrome: a clinical-pathologic-CT correlation. AJR Am J Roentgenol 1983, 140:861-868.
76. Bursztyn EM, Lee BC, Bauman J CT of acquired immunodeficiency syndrome. AJNR Am J Neuroradiol 1984, 5:711-714.
77. Ciricillo SF, Rosenblum ML Imaging of solitary lesions in AIDS. J Neurosurg 1991, 74:1029.
78. Ciricillo SF, Rosenblum ML Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990, 73:720-724.
79. De La Paz R, Enzmann D Neuroradiology of acquired immunodeficiency syndrome. AIDS and the nervous system 1988, 121-154. Raven Press, New York. M.L. Rosenblum (Ed.).
80. Kupfer MC, Zee C-S, Colletti PM, et al. MRI evaluation of AIDS-related encephalopathy: Toxoplasmosis vs lymphoma. Mag Res Imag 1990, 8:51-57.
81. Levy RM, Mills CM, Posin JP, et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: A prospective CT/MRI study. J Acquir Immune Defic Syndr 1990, 3:461-471.
82. Post MJ, Sheldon JJ, Hensley GT, et al. Central nervous system disease in acquired immunodeficiency syndrome: prospective correlation using CT, MR imaging, and pathologic studies. Radiology 1986, 158:141-148.
83. Luft BJ, Hafner R, Korzun AH, et al. TE in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993, 329:995-1000.
84. Levy RM, Rosenbloom S, Perrett LV Neuroradiologic findings in AIDS: a review of 200 cases. AJR Am J Roentgenol 1986, 147:977-983.
85. Laissy J, Soyer P, Parlier C, et al. Persistent enhancement after treatment for cerebral toxoplasmosis in patients with AIDS: predictive value for subsequent recurrence. AJNR Am J Neuroradiol 1994, 15:1773-1778.
86. Dina TS Primary central nervous system lymphoma versus toxoplasmosis in AIDS. Radiology 1991, 179:823-828.
87. O'Malley J, Ziessman H, Kumar P, et al. Diagnosis of intracranial lymphoma in patients with AIDS: value of 201TI single-photon emission computed tomography. AJR Am J Roentgenol 1994, 163:417-421.
88. Lorberboym M, Estok L, Machac J, et al. Rapid differential diagnosis of cerebral toxoplasmosis and primary central nervous system lymphoma by Thallium-201 SPECT. J Nucl Med 1996, 37:1150-1154.
89. Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998, 39:1366-1369.
90. Hoffman J, Waskin H, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmaliganant central nervous system lesions in patients with AIDS. J Nucl Med 1993, 34:567-575.
91. Pierce M, Johnson M, Maciunas R, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995, 123:594-598.
92. Luft BJ, Remington JS Toxoplasmosis of the central nervous system. Current clinical topics in infectious diseases 1985, 315-358. McGraw-Hill, New York. 6 edn. J.S. Remington, M.N. Swartz (Eds.).
93. Wijdicks EFM, Borleffs JCC, Hoepelman AIM, et al. Fatal disseminated hemorrhagic TE as the initial manifestation of AIDS. Ann Neurol 1991, 29:683-686.
94. Conley FK, Jenkins KA, Remington JS Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981, 12:690-698.
95. Cerezo L, Alvarez M, Price G Electron microscopic diagnosis of cerebral toxoplasmosis. Case report. J Neurosurg 1985, 63:470-472.
96. DeMent SH, Cox MC, Gupta PK Diagnosis of central nervous system Toxoplasma gondii from the cerebrospinal fluid in a patient with acquired immunodeficiency syndrome. Diagn Cytopathol 1987, 3:148-151.
97. Bottone EJ Diagnosis of acute pulmonary toxoplasmosis by visualization of invasive and intracellular tachyzoites in Giemsa-stained smears of bronchoalveolar lavage fluid. J Clin Microbiol 1991, 29:2626-2627.
98. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Invest N Engl J Med 1998, 338:853-860.
99. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
100. Ammassari A, Scoppettuolo G, Murri R, et al. Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:365-371.
101. Belanger F, Derouin F, Grangeot-Keros L, et al. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 1999, 28:575-581.
102. Abgrall S, Rabaud C, Costagliola D Incidence and risk factors for TE in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001, 33:1747-1755.
103. Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: A decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurol 1997, 48:687-694.
104. Raffi F, Aboulker JP, Michelet C, et al. A prospective study of criteria for the diagnosis of TE in 186 AIDS patients. AIDS 1997, 11:177-184.
105. Leport C, Remington JS Toxoplasmose au cours du SIDA. Presse Med 1992, 21:1165-1171.
106. Katlama C Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of TE in AIDS. Eur J Clin Microbiol Infect Dis 1991, 10:189-191.
107. Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for TE in patients with aids. Clin Infect Dis 1996, 22:268-275.
108. Canessa A, Del Bono V, De Leo P, et al. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Inf Dis 1992, 11:125-130.
109. Solbreux P, Sonnet J, Zech F A retrospective study about the use of cotrimoxazole as diagnostic support and treatment of suspected cerebral toxoplasmosis in AIDS. Acta Clin Belg 1990, 45:85-96.
110. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of TE in patients with AIDS. Ital Collab Study Group Antimicrob Agents Chemother 1998, 42:1346-1349.
111. Kaufman HE, Geisler PH The hematologic toxicity of pyrimethamine (Daraprim) in man. Arch Ophthalmol 1960, 64:140-146.
112. Myatt AV, Coatney GR, Hernandez T, et al. A further study of the toxicity of pyrimethamine (Daraprim) in man. Am J Trop Med Hyg 1953, 2:1000-1001.
113. Myatt AV, Hernandez T, Coatney GR Studies in human malaria. XXXIII. The toxicity of pyrimethamine (Daraprim) in man. Am J Trop Med Hyg 1953, 2:788-794.
114. Frenkel JK, Hitchings GH Relative reversal by vitamins (p-Aminobenzoic, folic and folinic acids) of the effects of sulfadiazine and pyrimethamine on toxoplasma, mouse and man. Antibiot Chemother 1957, 7:630-638.
115. Nixon PF, Bertino JR Effective absorption and utilization of oral formyltetrahydrofolate in man. N Engl J Med 1972, 286:175-179.
116. Rousseau F, Pueyo S, Morlat P, et al. Increased risk of TE in human immunodeficiency virus-infected patients with pyrimethamine-related rash. Clin Infect Dis 1997, 24:396-402.
117. Guichard A, Zamora L, Calmes E, et al. Cutaneous Side Effects: A Major Problem In The Treatment of Toxoplasmosis Encephalitis (TE). VII International Conference on AIDS, Florence, Italy: 1991.
118. Gluckstein D, Ruskin J Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995, 20:849-853.
119. Molina J, Belenfant X, Doco-Lecompte T, et al. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS 1991, 5:587-589.
120. Dannemann BR, Israelski DM, Remington JS Treatment of TE with intravenous clindamycin. Arch Intern Med 1988, 148:2477-2482.
121. Fernandez-Martin J, Leport C, Morlat P, et al. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991, 35:2049-2052.
122. Leport C, Bastuji-Garin S, Perronne C, et al. (Letter to the editor) An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis. J Infect Dis 1989, 160:557-558.
123. Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of TE in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002, 34:1243-1250.
124. Saba J, Morlat P, Raffi F, et al. Pyrimethamine plus azithromycin for treatment of acute TE in patients with AIDS. Eur J Clin Microbiol Infect Dis 1993, 12:853-856.
125. Jacobson JM, Hafner R, Remington J, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of TE in AIDS. AIDS 2001, 15:583-589.
126. Rabaud C, May T, Lucet JC, et al. Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French national study. Clin Infect Dis 1996, 23:1249-1254.
127. Walckenaer G, Leport C, Longuet P, et al. Relapses of brain toxoplasmosis (BT) in 15 AIDS patients. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois: 1991.
128. Leport C, Tournerie C, Raguin G, et al. Long-term follow-up of patients with AIDS on maintenance therapy for toxoplasmosis. Eur J Clin Microbiol Infect Dis 1991, 10:191-193.
129. Podzamczer D, Miro J, Bolao F, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimetha mine to prevent recurrent TE in patients with AIDS. Ann Intern Med 1995, 123:175-180.
130. Heald A, Flepp M, Chave J-P, et al. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1991, 115:760-763.
131. de Gans J, Portegies P, Reiss P, et al. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J AIDS 1992, 5:137-142.
132. Foppa CU, Bini T, Gregis G, et al. A retrospective study of primary and maintenance therapy of TE with oral clindamycin and pyrimethamine. Eur J Clin Microbiol Infect Dis 1991, 10:187-189.
133. Girard P, Lepretre A, Detruchis P, et al. Failure of pyrimethamine-clindamycin combinations for prophylaxis of Pneumocystis carinii pneumonia. Lancet 1989, 8652:1459.
134. Ruf B, Schurmann D, Bergmann F, et al. Efficacy of pyrimethamine/sulfadoxine in the prevention of TE relapses and Pneumocystis carinii pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993, 12:325-329.
135. Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term suppressive therapy for TE in patients with AIDS and multiple drug intolerance. AIDS 1996, 10:1107-1112.
136. Torres R, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of TE in patients with AIDS. Clin Infect Dis 1997, 24:422-429.
137. Mallolas J, Zamora L, Gatell JM, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993, 7:59-64.
138. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005, 40:138-140.
139. Leport C, Chěne G, Morlat P, et al. Pyrimethamine for primary prophylaxis of TE in patients with human immunodeficiency virus infection: A double-blind, randomized trial. J Infect Dis 1996, 173:91-97.
140. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for TE in patients with AIDS. Ann Intern Med 1992, 117:106-111.
141. Nicholas P, Pierone G, Lin J, et al. Trimethoprim-sulfamethoxazole in the prevention of cerebral toxoplasmosis. 6th International Conference on AIDS, San Francisco, CA: 1990.
142. O'Farrell N, Bradbeer C, Fitt S, et al. Cerebral toxoplasmosis and co-trimoxazole prophylaxis. Lancet 1991, 337:986.
143. Podzamczer D, Salazar A, Jiménez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995, 122:755-761.
144. Podzamczer D, Santin M, Jimenez J, et al. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. Aids 1993, 7:501-506.
145. Ruskin J, LaRiviere M Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991, 337:468-471.
146. Ribera E, Fernandez-Sola A, Juste C, et al. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of TE in human immunodeficiency virus-infected patients. Clinical Infect Dis 1999, 29:1461-1466.
147. Clumeck N Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe. Eur J Clin Microbiol Infect Dis 1991, 10:177-178.
148. Clotet B, Sirera G, Romeu J, et al. Twice-Weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS 1991, 5:601-602.
149. Köppen S, Grunewald T, Jautzke G, et al. Prevention of Pneumocystis carinii pneumonia and TE in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine. Clin Investig 1992, 70:508-512.
150. Girard P-M, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as a primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993, 328:1514-1520.
151. Liesenfeld O, Wong SY, Remington JS Toxoplasmosis in the setting of AIDS. Textbook of AIDS medicine 1999, 225-259. Williams & Wilkins, Baltimore. 2nd edn. J.G. Bartlett, T.C. Merigan, D. Bolognesi (Eds.).
152. Subauste CS, Wessendarp M, Smulian AG, et al. Role of CD40 ligand signaling in defective type 1 cytokine response in human immunodeficiency virus infection. J Infect Dis 2001, 183:1722-1731.
153. Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of Primary Prophylaxis for Pneumocystis carinii, pneumonia and TE in human immunodeficiency virus Type I-infected patients: The changes in opportunistic prophylaxis study. J Infect Dis 2000, 181:1635-1642.
154. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-l-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999, 340:1301-1306.
155. Kirk O, Lundgren JD, Pedersen C, et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?. AIDS 1999, 13:1647-1651.
156. Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study Lancet 2000, 355:2217-2218.
157. Miro JM, Podzamczer D, Pena JM, et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-1 infected patients after immunological recovery with HAART. Final results of the GESIDA 94/98 study. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA: 1998.
158. Soriano V, Dona C, Rodriguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000, 14:383-386.